Kumaraguru Raja
Stock Analyst at Brookline Capital
(0.26)
# 4,410
Out of 5,173 analysts
17
Total ratings
20%
Success rate
-22.56%
Average return
Main Sectors:
Top Industries:
Stocks Rated by Kumaraguru Raja
| Stock | Action | Price Target | Current | Upside | Ratings | Updated | |
|---|---|---|---|---|---|---|---|
| INTS Intensity Therapeutics | Upgrades: Buy | $75 | $6.22 | +1,105.79% | 1 | Aug 12, 2025 | |
| PALI Palisade Bio | Maintains: Buy | $16 | $1.91 | +737.70% | 2 | May 13, 2025 | |
| QNCX Quince Therapeutics | Initiates: Buy | $9 | $0.10 | +8,758.27% | 1 | Dec 18, 2024 | |
| SABS SAB Biotherapeutics | Initiates: Buy | $8 | $3.93 | +103.56% | 1 | Jun 7, 2024 | |
| FBRX Forte Biosciences | Initiates: Buy | $100 | $25.61 | +290.47% | 2 | May 30, 2024 | |
| OTLK Outlook Therapeutics | Downgrades: Hold | n/a | $0.32 | - | 1 | Aug 30, 2023 | |
| ADIL Adial Pharmaceuticals | Reiterates: Buy | $3,750 | $1.84 | +203,704.35% | 2 | Jul 11, 2023 | |
| GNTA Genenta Science | Assumes: Buy | $15 | $0.67 | +2,153.94% | 1 | Jun 29, 2023 | |
| ATYR aTyr Pharma | Reinstates: Buy | $9 | $0.83 | +987.74% | 1 | Mar 6, 2023 | |
| RAIN Rain Enhancement Technologies Holdco | Reinstates: Buy | $21 | $3.04 | +590.79% | 1 | Jan 31, 2023 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reinstates: Buy | $90 | $56.26 | +59.97% | 1 | Dec 9, 2022 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Buy | $290 → $310 | $2.30 | +13,378.26% | 2 | May 18, 2022 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Buy | $33,600 | $1.57 | +2,140,027.39% | 1 | Sep 21, 2021 |
Intensity Therapeutics
Aug 12, 2025
Upgrades: Buy
Price Target: $75
Current: $6.22
Upside: +1,105.79%
Palisade Bio
May 13, 2025
Maintains: Buy
Price Target: $16
Current: $1.91
Upside: +737.70%
Quince Therapeutics
Dec 18, 2024
Initiates: Buy
Price Target: $9
Current: $0.10
Upside: +8,758.27%
SAB Biotherapeutics
Jun 7, 2024
Initiates: Buy
Price Target: $8
Current: $3.93
Upside: +103.56%
Forte Biosciences
May 30, 2024
Initiates: Buy
Price Target: $100
Current: $25.61
Upside: +290.47%
Outlook Therapeutics
Aug 30, 2023
Downgrades: Hold
Price Target: n/a
Current: $0.32
Upside: -
Adial Pharmaceuticals
Jul 11, 2023
Reiterates: Buy
Price Target: $3,750
Current: $1.84
Upside: +203,704.35%
Genenta Science
Jun 29, 2023
Assumes: Buy
Price Target: $15
Current: $0.67
Upside: +2,153.94%
aTyr Pharma
Mar 6, 2023
Reinstates: Buy
Price Target: $9
Current: $0.83
Upside: +987.74%
Rain Enhancement Technologies Holdco
Jan 31, 2023
Reinstates: Buy
Price Target: $21
Current: $3.04
Upside: +590.79%
Dec 9, 2022
Reinstates: Buy
Price Target: $90
Current: $56.26
Upside: +59.97%
May 18, 2022
Maintains: Buy
Price Target: $290 → $310
Current: $2.30
Upside: +13,378.26%
Sep 21, 2021
Initiates: Buy
Price Target: $33,600
Current: $1.57
Upside: +2,140,027.39%